KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Raw Materials: 2017-2020

Historic Raw Materials for Aquestive Therapeutics (AQST) over the last 4 years, with Dec 2020 value amounting to $789,000.

  • Aquestive Therapeutics' Raw Materials fell 35.18% to $833,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $833,000, marking a year-over-year decrease of 35.18%. This contributed to the annual value of $789,000 for FY2020, which is 36.58% down from last year.
  • According to the latest figures from FY2020, Aquestive Therapeutics' Raw Materials is $789,000, which was down 36.58% from $1.2 million recorded in FY2019.
  • Over the past 5 years, Aquestive Therapeutics' Raw Materials peaked at $1.3 million during FY2018, and registered a low of $725,000 during FY2017.
  • Its 3-year average for Raw Materials is $1.1 million, with a median of $1.2 million in 2019.
  • In the last 5 years, Aquestive Therapeutics' Raw Materials surged by 76.97% in 2018 and then plummeted by 36.58% in 2020.
  • Yearly analysis of 4 years shows Aquestive Therapeutics' Raw Materials stood at $725,000 in 2017, then soared by 76.97% to $1.3 million in 2018, then decreased by 3.04% to $1.2 million in 2019, then crashed by 36.58% to $789,000 in 2020.